IL160721A0 - Crystalline forms of valacyclovir hydrochloride - Google Patents

Crystalline forms of valacyclovir hydrochloride

Info

Publication number
IL160721A0
IL160721A0 IL16072102A IL16072102A IL160721A0 IL 160721 A0 IL160721 A0 IL 160721A0 IL 16072102 A IL16072102 A IL 16072102A IL 16072102 A IL16072102 A IL 16072102A IL 160721 A0 IL160721 A0 IL 160721A0
Authority
IL
Israel
Prior art keywords
crystalline forms
valacyclovir hydrochloride
valacyclovir
hydrochloride
crystalline
Prior art date
Application number
IL16072102A
Other languages
English (en)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL160721A0 publication Critical patent/IL160721A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
IL16072102A 2001-09-07 2002-09-06 Crystalline forms of valacyclovir hydrochloride IL160721A0 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US31785001P 2001-09-07 2001-09-07
US34227301P 2001-12-21 2001-12-21
US38650502P 2002-06-05 2002-06-05
US40383802P 2002-08-14 2002-08-14
PCT/US2002/028517 WO2003022209A2 (fr) 2001-09-07 2002-09-06 Formes cristallines de chlorhydrate de valacyclovir

Publications (1)

Publication Number Publication Date
IL160721A0 true IL160721A0 (en) 2004-08-31

Family

ID=27502150

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16072102A IL160721A0 (en) 2001-09-07 2002-09-06 Crystalline forms of valacyclovir hydrochloride

Country Status (16)

Country Link
US (2) US6849736B2 (fr)
EP (1) EP1436295A4 (fr)
JP (2) JP5043286B2 (fr)
KR (1) KR100774271B1 (fr)
CN (1) CN1551880A (fr)
CA (1) CA2457835A1 (fr)
CZ (1) CZ2004446A3 (fr)
HR (1) HRP20040321A2 (fr)
HU (1) HUP0500753A3 (fr)
IL (1) IL160721A0 (fr)
IN (2) IN2004MU00133A (fr)
MX (1) MXPA04002192A (fr)
NO (1) NO20041449L (fr)
PL (1) PL374179A1 (fr)
SK (1) SK1592004A3 (fr)
WO (1) WO2003022209A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040145A1 (fr) * 2001-11-05 2003-05-15 Glaxo Group Limited Forme cristalline anhydre du valaciclovir chlorhydrate
MX242714B (es) * 2001-11-14 2006-12-15 Teva Pharma Sintesis y purificacion de valaciclovir.
WO2004000265A2 (fr) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Procede de preparation de formulations solides de comprimes de chlorhydrate de valacyclovir
US6992219B2 (en) * 2002-08-09 2006-01-31 Cephalon France Modafinil polymorphic forms
US20050043329A1 (en) * 2002-09-06 2005-02-24 Shlomit Wizel Crystalline forms of valacyclovir hydrochloride
ATE335743T1 (de) * 2002-10-16 2006-09-15 Teva Pharma Verfahren zur verminderung von restalkoholen im kristallinen valacyclovir-hydrochlorid
US20050059684A1 (en) * 2002-10-16 2005-03-17 Ben-Zion Dolitzky Method for reducing residual alcohols in crystalline valacyclovir hydrochloride
US7786302B2 (en) * 2003-05-30 2010-08-31 Eczacibasi-Zentiva Kimyasal Urunler Sanayi Ve Ticaret A.S. Crystalline forms of valacyclovir hydrochloride
CA2527708A1 (fr) 2003-06-02 2005-01-06 Teva Pharmaceutical Industries Ltd. Formes cristallines de chlorhydrate de valacyclovir
US7368591B2 (en) 2003-09-19 2008-05-06 Cephalon France Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
EP1541133B1 (fr) * 2003-12-09 2005-08-10 Helm AG Formulation pharmaceutique de valaciclovir
JP2008504255A (ja) * 2004-06-30 2008-02-14 テバ ファーマシューティカル インダストリーズ リミティド 結晶塩酸バラシクロビル中の残留アルコールを低減する方法
WO2006035452A1 (fr) * 2004-09-27 2006-04-06 Matrix Laboratories Ltd Nouveau pseudomorphe d'hydrochlorure de valaciclovir
EP1746098A1 (fr) 2005-07-21 2007-01-24 SOLMAG S.p.A. Des polymorphes de valacyclovir et procédé pour leur fabrication
US7872075B2 (en) * 2005-10-07 2011-01-18 Exxonmobil Chemical Patents Inc. Peroxide-cured thermoplastic vulcanizates and process for making the same
US20080167325A1 (en) * 2006-12-27 2008-07-10 Bs Praveen Kumar Valacyclovir compositions
US20080281099A1 (en) * 2007-05-07 2008-11-13 Mayur Devjibhai Khunt Process for purifying valacyclovir hydrochloride and intermediates thereof
JPWO2009031576A1 (ja) * 2007-09-03 2010-12-16 味の素株式会社 バラシクロビル塩酸塩結晶の製造方法
US20090076039A1 (en) * 2007-09-14 2009-03-19 Protia, Llc Deuterium-enriched valacyclovir
WO2011158252A1 (fr) 2010-06-15 2011-12-22 Matrix Laboratories Ltd Méthode de préparation de la forme polymorphe ii du chlorhydrate de valacyclovir
GB201222287D0 (en) * 2012-12-11 2013-01-23 Ct For Process Innovation Ltd Methods for making active crystalline materials
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途
KR20200022712A (ko) * 2018-08-23 2020-03-04 주식회사 오스코텍 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4199574A (en) 1974-09-02 1980-04-22 Burroughs Wellcome Co. Methods and compositions for treating viral infections and guanine acyclic nucleosides
AP55A (en) * 1987-08-15 1989-09-26 The Wellcome Foundation Ltd Therapeutic Acyclic Nucleosides
GB8719367D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Therapeutic compounds
EP0702682B1 (fr) * 1993-06-10 2001-03-14 Rolabo Sl Procede de preparation d'ester aminoacide d'un analogue de nucleoside
US5840891A (en) * 1994-07-28 1998-11-24 Syntex (U.S.A.) Inc. 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
GB9501178D0 (en) * 1995-01-20 1995-03-08 Wellcome Found Guanine derivative
CA2243237C (fr) * 1996-01-19 2008-09-02 Glaxo Group Limited Utilisation de valaciclovir dans la fabrication d'un medicament destine au traitement de l'herpes genital
AU1592897A (en) * 1996-01-26 1997-08-20 F. Hoffmann-La Roche Ag Process for preparing purine derivatives
US5840890A (en) * 1996-01-26 1998-11-24 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US5756736A (en) * 1996-01-26 1998-05-26 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)methoxy-1,3-propanediol derivative
US6040446A (en) * 1996-01-26 2000-03-21 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative
IT1283447B1 (it) * 1996-07-18 1998-04-21 Ind Chimica Srl Processo di preparazione del valaciclovir e relativi intermedi
WO2003040145A1 (fr) * 2001-11-05 2003-05-15 Glaxo Group Limited Forme cristalline anhydre du valaciclovir chlorhydrate
MX242714B (es) * 2001-11-14 2006-12-15 Teva Pharma Sintesis y purificacion de valaciclovir.
WO2004000265A2 (fr) * 2002-06-24 2003-12-31 Ranbaxy Laboratories Limited Procede de preparation de formulations solides de comprimes de chlorhydrate de valacyclovir
AU2003289995A1 (en) * 2002-12-09 2004-06-30 Texcontor Etablissement Anhydrous crystalline form of valacyclovir hydrochloride
US7786302B2 (en) * 2003-05-30 2010-08-31 Eczacibasi-Zentiva Kimyasal Urunler Sanayi Ve Ticaret A.S. Crystalline forms of valacyclovir hydrochloride
EP1746098A1 (fr) * 2005-07-21 2007-01-24 SOLMAG S.p.A. Des polymorphes de valacyclovir et procédé pour leur fabrication
US20070112193A1 (en) * 2005-11-14 2007-05-17 Khunt Mayur D Valacyclovir process

Also Published As

Publication number Publication date
CZ2004446A3 (cs) 2005-01-12
MXPA04002192A (es) 2005-02-17
CA2457835A1 (fr) 2003-03-20
HUP0500753A2 (hu) 2005-11-28
SK1592004A3 (sk) 2005-03-04
EP1436295A2 (fr) 2004-07-14
JP5043286B2 (ja) 2012-10-10
WO2003022209A3 (fr) 2003-11-27
KR20040036932A (ko) 2004-05-03
EP1436295A4 (fr) 2007-07-11
IN2006MU00429A (fr) 2007-08-17
WO2003022209A2 (fr) 2003-03-20
HRP20040321A2 (en) 2004-08-31
JP2012162565A (ja) 2012-08-30
KR100774271B1 (ko) 2007-11-08
HUP0500753A3 (en) 2006-05-29
WO2003022209A9 (fr) 2004-04-08
IN2004MU00133A (fr) 2005-04-29
US20030114470A1 (en) 2003-06-19
JP2005526694A (ja) 2005-09-08
NO20041449L (no) 2004-04-06
PL374179A1 (en) 2005-10-03
US6849736B2 (en) 2005-02-01
US20050187229A1 (en) 2005-08-25
CN1551880A (zh) 2004-12-01

Similar Documents

Publication Publication Date Title
HUP0500753A3 (en) Crystalline forms of valacyclovir hydrochloride
HK1208446A1 (en) Derivatives of uk-2a uk-2a
IL172006A0 (en) Novel crystalline forms of valacyclovir hydrochloride
HUP0600337A2 (en) Modification of feeding behavior
IL159426A0 (en) Polymorphic forms of 1-4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
IL176141A0 (en) Crystalline forms of valacyclovir hydrochloride
AU1234002A (en) Crystalline forms of venlafaxine hydrochloride
EP1390052A4 (fr) Inhibition de la kinase jun
GB2383038B (en) Anhydrous crystal form of valaciclovir hydrochloride
IL158334A0 (en) Polymorphs of fexofenadine hydrochloride
AU2003232719A1 (en) Novel crystalline forms of valacyclovir hydrochloride
AU2003245027A1 (en) Novel crystalline forms of ziprasidone hydrochloride
IL166592A0 (en) Novel crystalline forms of gatifloxacin
AU2003289995A1 (en) Anhydrous crystalline form of valacyclovir hydrochloride
IL165115A0 (en) Novel crystalline forms of gatifloxacin
EP1367996A4 (fr) Suspension d'hydrochlorure de ceftiofur a liberation prolongee
IL159266A0 (en) Crystalline forms of fexofenadine and processes for the preparation thereof
ZA200601326B (en) Crystalline forms of valacyclovir hydrochloride
IL165690A0 (en) Novel crystalline forms of gatifloxacin
IS7169A (is) Kristölluð form valasýklóvírhýdróklóríðs
GB0329236D0 (en) Crystalline forms of (+)- and (-)- erthro-mefloquine hydrochloride
IL160924A0 (en) Stabilization of amrubicin hydrochloride
HU0104370D0 (en) Honeyed schnaps of oerseg
AU2002237189A1 (en) New use of phencynonate hydrochloride
AU2002238356A1 (en) New use of phencynonate hydrochloride